|
Title
|
|
|
|
EGFR-directed therapies in squamous cell carcinoma of the head and neck
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| The EGF receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). EGFR-directed therapies include monoclonal antibodies and tyrosine kinase inhibitors. The addition of the monoclonal antibody cetuximab to irradiation improves the outcome in locoregionally advanced SCCHN. The addition of an EGFR-directed monoclonal antibody, particularly cetuximab, to a platinum-based chemotherapy improves the outcome in recurrent/metastatic SCCHN. EGFR-directed monoclonal antibodies have activity in platinum-refractory SCCHN, although the benefit might be less than expected. The activity of EGFR-directed tyrosine kinase inhibitors in SCCHN so far has been disappointing. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (book)
|
|
|
|
EGFR inhibitors in cancer treatment / Ciardiello, Fortunato [edit.]
|
|
|
Publication
|
|
|
|
London
:
Future Medicine
,
2012
|
|
|
ISBN
|
|
|
|
978-1-78084-026-0
|
|
|
DOI
|
|
|
|
10.2217/EBO.11.366
|
|
|
Volume/pages
|
|
|
|
p. 60-71
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|